Raymond James Financial
TXMD icon

Raymond James Financial’s TherapeuticsMD TXMD Stock Holding History

Raymond James Financial’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-532
Closed -$617 – 6664
2025
Q2 		$617 Buy
+532
New +$645 ﹤0.01% 6646

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James Financial's TXMD Position: Q3 2025 in Review

Raymond James Financial sold out of TherapeuticsMD (TXMD) in Q3 2025, closing a stake of 532 shares — an estimated $617 sold.

Raymond James Financial first reported a position in TXMD in Q2 2025 and held it in 1 quarter. The position peaked at $617 in Q2 2025. 46 funds tracked by Wall St. Rank hold TXMD as of Q3 2025.

  • Raymond James Financial reported no remaining TherapeuticsMD position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 532 TherapeuticsMD shares in Q3 2025, an estimated $617.
  • Raymond James Financial first reported a position in TherapeuticsMD in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's TherapeuticsMD position peaked at $617 in Q2 2025.
  • 46 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.